U.S. FDA Approves Requip®XL?, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For...

Main Category: Parkinson's Disease Also Included In: GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Itis the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson's disease. The product should be available in U.S. pharmacies in mid-July 2008. Patients with Parkinson's disease may experience what is commonly known as "off" time when their medication wears off and their symptoms return. Symptoms such as slowness of movement, tremor, and rigidity can be problematic for these patients, causing simple activities and movement to become difficult. Results from a pivotal efficacy and safety trial showed that adding extended-release ropinirole to patients' existing levodopa... [read full story]